The Value of Personalized Outcome Assessment: Goal Attainment Scaling (GAS) in Patient- Focused Drug Development:

Transforming Reimbursement Decisions in Alzheimer’s Disease - A Case from Canada

This white paper, developed in collaboration with Ardea Outcomes' founder, Dr. Kenneth Rockwood, establishes the compelling value of Goal Attainment Scaling (GAS) as a personalized outcome assessment within clinical drug development programs.

GAS addresses key limitations of traditional endpoints by quantifying treatment effects on individualized, patient-meaningful goals. Drawing on case studies from Alzheimer’s disease (the VISTA and ACADIE trials) in Canada, the paper demonstrates how GAS data played a pivotal role in both securing and shaping drug reimbursement decisions. By directly informing HTA evaluations, GAS helped expand patient access and validate the real-world value of the interventions.